GE Healthcare has released its Invenia automated breast ultrasound (ABUS) supplementary screening examination in Europe.
The company is highlighting the device at the two-day European Society of Breast Imaging (EUSOBI) annual meeting, which began in London on 2 October.
Using Invenia ABUS in addition to mammography increases the likelihood of finding invasive breast cancers in women with dense tissue by 55%, according to GE. It features 3D ultrasound technology, GE's Reverse Curve transducer for conforming to a woman's anatomy, and Compression Assist, a feature that applies light levels of compression to the breast for better image reproducibility, the company said.
GE received clearance for the device from the U.S. Food and Drug Administration (FDA) in 2014.